Cargando…

The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)

BACKGROUND: Fenoverine is a spasmolytic drug that has been used to treat abdominal pain. Although sporadic case reports or case series of rhabdomyolysis associated with fenoverine have been published, there are no studies evaluating the incidence, risk factors, and clinical outcomes of rhabdomyolysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Junhyeong, Na, Jeonggu, Bae, Eunjin, Lee, Tae Won, Jang, Ha Nee, Cho, Hyun Seop, Chang, Se-Ho, Park, Dong Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183697/
https://www.ncbi.nlm.nih.gov/pubmed/32334639
http://dx.doi.org/10.1186/s40360-020-00408-3
_version_ 1783526474182033408
author Cho, Junhyeong
Na, Jeonggu
Bae, Eunjin
Lee, Tae Won
Jang, Ha Nee
Cho, Hyun Seop
Chang, Se-Ho
Park, Dong Jun
author_facet Cho, Junhyeong
Na, Jeonggu
Bae, Eunjin
Lee, Tae Won
Jang, Ha Nee
Cho, Hyun Seop
Chang, Se-Ho
Park, Dong Jun
author_sort Cho, Junhyeong
collection PubMed
description BACKGROUND: Fenoverine is a spasmolytic drug that has been used to treat abdominal pain. Although sporadic case reports or case series of rhabdomyolysis associated with fenoverine have been published, there are no studies evaluating the incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription. METHODS: We retrospectively reviewed the medical records of 22 patients admitted with rhabdomyolysis associated with fenoverine from January 1999 to December 2014, while excluding other well-known risk factors of rhabdomyolysis. This period was subdivided into two periods, January 1999–December 2007 and January 2008–December 2014. We analyzed the clinical and laboratory characteristics, and the prognosis of fenoverine associated with rhabdomyolysis for these times. RESULTS: The incidence of rhabdomyolysis associated with fenoverine was 0.27% during the total period (22/8257), 0.34% in the first period (18/5298), and 0.14% in the second period (4/2959) (p < 0.001). Rhabdomyolysis occurred in 19 liver cirrhosis (LC) patients (2.03%), whereas only 3 cases (0.04%) occurred in non-LC patients (p < 0.001). Drug duration, total dose, muscle enzymes, and clinical characteristics were not different between the LC and non-LC groups. Acute renal failure (ARF) occurred in 5 patients in the LC group and 2 patients in the non-LC group (p = 0.227). Severity of hepatic derangement according to the Child-Pugh classification was not different between the ARF group and non-ARF group (p = 0.227). Four patients died, having complications of oliguric ARF (p = 0.005) and underlying severe LC (p = 0.017). Higher serum lactate dehydrogenase, blood urea nitrogen, creatinine, and potassium levels but lower serum sodium levels were found in the group that died (p = 0.001). CONCLUSIONS: Physicians should carefully prescribe fenoverine because it may cause rhabdomyolysis, especially in patients with LC.
format Online
Article
Text
id pubmed-7183697
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71836972020-04-29 The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014) Cho, Junhyeong Na, Jeonggu Bae, Eunjin Lee, Tae Won Jang, Ha Nee Cho, Hyun Seop Chang, Se-Ho Park, Dong Jun BMC Pharmacol Toxicol Research Article BACKGROUND: Fenoverine is a spasmolytic drug that has been used to treat abdominal pain. Although sporadic case reports or case series of rhabdomyolysis associated with fenoverine have been published, there are no studies evaluating the incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription. METHODS: We retrospectively reviewed the medical records of 22 patients admitted with rhabdomyolysis associated with fenoverine from January 1999 to December 2014, while excluding other well-known risk factors of rhabdomyolysis. This period was subdivided into two periods, January 1999–December 2007 and January 2008–December 2014. We analyzed the clinical and laboratory characteristics, and the prognosis of fenoverine associated with rhabdomyolysis for these times. RESULTS: The incidence of rhabdomyolysis associated with fenoverine was 0.27% during the total period (22/8257), 0.34% in the first period (18/5298), and 0.14% in the second period (4/2959) (p < 0.001). Rhabdomyolysis occurred in 19 liver cirrhosis (LC) patients (2.03%), whereas only 3 cases (0.04%) occurred in non-LC patients (p < 0.001). Drug duration, total dose, muscle enzymes, and clinical characteristics were not different between the LC and non-LC groups. Acute renal failure (ARF) occurred in 5 patients in the LC group and 2 patients in the non-LC group (p = 0.227). Severity of hepatic derangement according to the Child-Pugh classification was not different between the ARF group and non-ARF group (p = 0.227). Four patients died, having complications of oliguric ARF (p = 0.005) and underlying severe LC (p = 0.017). Higher serum lactate dehydrogenase, blood urea nitrogen, creatinine, and potassium levels but lower serum sodium levels were found in the group that died (p = 0.001). CONCLUSIONS: Physicians should carefully prescribe fenoverine because it may cause rhabdomyolysis, especially in patients with LC. BioMed Central 2020-04-25 /pmc/articles/PMC7183697/ /pubmed/32334639 http://dx.doi.org/10.1186/s40360-020-00408-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Cho, Junhyeong
Na, Jeonggu
Bae, Eunjin
Lee, Tae Won
Jang, Ha Nee
Cho, Hyun Seop
Chang, Se-Ho
Park, Dong Jun
The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)
title The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)
title_full The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)
title_fullStr The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)
title_full_unstemmed The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)
title_short The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)
title_sort incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in south korea (1999–2014)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183697/
https://www.ncbi.nlm.nih.gov/pubmed/32334639
http://dx.doi.org/10.1186/s40360-020-00408-3
work_keys_str_mv AT chojunhyeong theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT najeonggu theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT baeeunjin theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT leetaewon theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT janghanee theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT chohyunseop theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT changseho theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT parkdongjun theincidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT chojunhyeong incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT najeonggu incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT baeeunjin incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT leetaewon incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT janghanee incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT chohyunseop incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT changseho incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014
AT parkdongjun incidenceriskfactorsandclinicaloutcomesofrhabdomyolysisassociatedwithfenoverineprescriptionaretrospectivestudyinsouthkorea19992014